Amryt Pharma PLC – Four Middle East Lojuxta® Distribution Agreements
Amryt, a biopharmaceutical company focused on rare and orphan diseases, is pleased to announce the signing of four further distribution agreements for Lojuxta® (lomitapide) across the Middle East, where the incidence of Homozygous Familial Hypercholesterolaemia (“HoFH”), the rare cholesterol disorder treated by Lojuxta, is relatively high.
The distribution agreements have been signed with Al Hafez Trading Establishment, which operates in Kuwait, Ebn Sina Medical, the leading medical organisation in Qatar, Muscat Pharmacy and Stores in Oman, and Goro Healthcare of the UAE and Bahrain. These agreements extend Amryt’s distribution network in the region and will provide HoFH patients with better access to care.
Since November 2017 Amryt has signed nine new distribution agreements for Lojuxta. The Company holds an exclusive licence to sell Lojuxta across Europe, the Middle East, Turkey, Israel, Russia, the Commonwealth of Independent States, and the Balkan states. The recent expansion of the licence agreement has increased the total number of addressable patients in Amryt’s territories by approximately 25%. Amryt generated revenues of €11.9m from sales of Lojuxta in 2017.
Joe Wiley, CEO of Amryt Pharma, commented: “Driving Lojuxta’s growth in new and existing territories is a core focus for Amryt in 2018. We are delighted to announce that we have further expanded our distribution network in the Middle East with additional agreements covering Kuwait, Qatar, Oman, the UAE and Bahrain. These agreements will ensure that we can respond effectively to physician requests for Lojuxta. The Middle East has a higher HoFH patient population per capita than Europe and we look forward to working closely with our new distribution partners to improve patient outcomes. We remain in discussions with other potential distribution partners as we continue to grow our network and market reach for Lojuxta.”